Abstract
Background: The efficacy and safety of conventional first-line chemotherapeutic regimens for the treatment of advanced biliary tract carcinomas (ABTCs) have been unsatisfactory. Objectives: We aimed to explore alternative chemotherapeutic regimens capable of providing a better efficacy and fewer side effects. Design: Multicentre, randomised, phase II clinical trial. Methods: Eligible patients with unresectable, recurrent, or metastatic biliary system tumours diagnosed by pathology or cytology between January 2021 and November 2022 were included. The participants were randomised to either a gemcitabine-cisplatin group (GC) or an albumin-paclitaxel-cisplatin group (NC). Progression-free survival (PFS) was the primary outcome, whereas overall survival (OS), and objective response rate (ORR) were the secondary outcomes. Results: The trial enrolled 75 patients and had a median follow-up period of 11 months. The median PFS (mPFS) was 7.8 m (95% CI: 5.4–14.0 m) in the NC group, and 7.0 m (95% CI: 3.9–10.1 m) in the GC group (p=0.0034, HR=0.5136). Median OS for the NC group was 12.4 m and for the GC group was 12.1 m (p=0.4592). PFS rates at 6 and 8 months were significantly higher in the NC group. Regarding safety, the NC group demonstrated significantly lower rates of thrombocytopenia. Conclusion: Compared with the GC group, the NC group showed a significantly increased mPFS and lower haematological toxicity, suggesting paclitaxel-based regimens as a viable alternative for first-line treatment of ABTCs.
Introduction
Biliary tract cancer (BTC), encompassing gallbladder cancer and cholangiocarcinoma, is an aggressive malignancy often diagnosed at advanced stages. For over a decade, the combination of gemcitabine and cisplatin (GC) has served as the global standard for first-line therapy. However, clinical outcomes remain suboptimal, and the regimen is frequently associated with significant hematological toxicities.
This multicentre Phase II trial investigated whether replacing gemcitabine with nab-paclitaxel (an albumin-bound formulation) could improve efficacy and safety. Nab-paclitaxel utilizes albumin transport pathways to enhance drug delivery to tumor cells, potentially offering a more targeted therapeutic approach.
Methods and Patient Characteristics
The study was conducted as an open-label, randomized, phase II trial across four cancer centers in China. A total of 75 patients with unresectable, recurrent, or metastatic BTC were enrolled and randomized into two groups:
- NC Group (n=37): Nab-paclitaxel (125 mg/m²) on days 1 and 8 plus Cisplatin (25 mg/m²) on days 1–3.
- GC Group (n=38): Gemcitabine (1000 mg/m²) on days 1 and 8 plus Cisplatin (25 mg/m²) on days 1–3.
Treatments were administered in 21-day cycles for up to six cycles, followed by S-1 maintenance therapy. The primary endpoint was progression-free survival (PFS).
As shown in the baseline data, the groups were well-balanced regarding age, sex, and tumor primary site, with the majority of patients in both cohorts presenting with liver metastasis at enrollment.
Results
Efficacy
The NC regimen demonstrated a statistically significant improvement in the primary endpoint. The median PFS was 7.8 months for the NC group versus 7.0 months for the GC group ($p=0.0034$; HR=0.5136). The 6-month PFS rate was also notably higher in the NC group (70.83% vs. 48.24%).
Despite the improvement in PFS, median overall survival (OS) did not differ significantly between the groups, reaching approximately 12 months for both (12.4m for NC vs. 12.1m for GC, $p=0.4592$). This suggests that while NC is more effective at delaying initial disease progression, subsequent lines of therapy or disease biology may influence long-term survival outcomes similarly.
Safety Profile
The study revealed a distinct shift in the toxicity profile between the two regimens:
- Hematological Toxicity: The NC group experienced significantly lower rates of thrombocytopenia (low platelet counts) compared to the GC group (32.4% vs. 50.0%, $p=0.041$).
- Neurological Toxicity: Conversely, sensory neuropathy was more prevalent in the NC group (62.1% vs. 36.8%, $p=0.028$), a known side effect of taxane-based therapies. These symptoms were generally manageable and improved post-treatment.
Discussion and Conclusion
The findings suggest that the NC regimen is a potent alternative to the standard GC combination for advanced biliary tract cancer. By leveraging the tumor-targeting properties of nab-paclitaxel, clinicians can achieve superior progression-free survival with a reduced burden of bone marrow suppression.
However, the study faced limitations, including a relatively small sample size and early termination due to the emergence of immunotherapy (PD-L1 inhibitors) as a new standard of care. Future research will focus on integrating these chemotherapy backbones with immune checkpoint inhibitors to determine if the PFS benefits of nab-paclitaxel can be translated into improved overall survival for patients with BTC.
Registration: ClinicalTrials.gov NCT04692051.
Summary updated